China CDE Approves Global Phase III Study of Olverembatinib for SDH-Deficient GIST
SUZHOU, China, and ROCKVILLE, Md., June 11, 2024 -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel...
SUZHOU, China, and ROCKVILLE, Md., June 11, 2024 -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel...